NCT06364410 Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors Status RECRUITING Phase PHASE1
NCT06331169 Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer Status RECRUITING Phase PHASE1
NCT06328387 HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06324357 Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread Status RECRUITING Phase PHASE1/PHASE2
NCT06311214 Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) Status RECRUITING Phase PHASE2
NCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06250777 Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases Status ENROLLING_BY_INVITATION Phase PHASE2
NCT06231693 Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil Status TERMINATED Phase N/A
NCT06210776 A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) Status RECRUITING Phase N/A
NCT06172127 PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06102824 Organoid-based Functional Precision Therapy for Advanced Breast Cancer Status RECRUITING Phase PHASE2
NCT06085755 Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06058988 Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Status RECRUITING Phase PHASE2
NCT05993234 A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) Status ACTIVE_NOT_RECRUITING Phase N/A
NCT05965479 Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer Status RECRUITING Phase PHASE2
NCT05953168 T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients Status NOT_YET_RECRUITING Phase PHASE2
NCT05950945 Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer Status RECRUITING Phase PHASE3
NCT05900206 Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer Status RECRUITING Phase PHASE2